

Pharmacy Management Drug Policy

SUBJECT: Step Therapy
POLICY NUMBER: PHARMACY-72
EFFECTIVE DATE: 10/2011
LAST REVIEW DATE: 02/16/2026

If the member's subscriber contract excludes coverage for a specific service or prescription drug, it is not covered under that contract. In such cases, medical or drug policy criteria are not applied. This drug policy applies to the following line/s of business:

Policy Application

Category:	<input checked="" type="checkbox"/> Commercial Group (e.g., EPO, HMO, POS, PPO)	<input type="checkbox"/> Medicare Advantage
	<input checked="" type="checkbox"/> On Exchange Qualified Health Plans (QHP)	<input type="checkbox"/> Medicare Part D
	<input checked="" type="checkbox"/> Off Exchange Direct Pay	<input checked="" type="checkbox"/> Essential Plan (EP)
	<input type="checkbox"/> Medicaid & Health and Recovery Plans (MMC/HARP)	<input checked="" type="checkbox"/> Child Health Plus (CHP)
	<input type="checkbox"/> Federal Employee Program (FEP)	<input type="checkbox"/> Ancillary Services
	<input type="checkbox"/> Dual Eligible Special Needs Plan (D-SNP)	

DESCRIPTION:

Step Therapy encourages use of safe, cost-effective medications within different therapeutic drug categories. The entry of new generics and cost-effective therapeutic alternatives has provided an opportunity to promote these therapies as first-line.

POLICY:

Step Therapy requires members try certain first-line options before other medications will be considered medically necessary for treatment of a specific condition. Step therapy requirements may apply to both brands and generics. Typically, first-line medications are classified as generics, but there are instances where brand name medications may be preferred.

Based upon our review and assessment of the peer-reviewed literature, these medications have been medically proven to be effective and therefore **medically necessary** for medical treatment if the request meets the following criteria:

ANTIBACTERIALS	
Drug	Requirement
Doryx, Doryx MPC	Coverage requires documentation of serious side effects or drug failure with immediate-release doxycycline AND immediate-release minocycline
Doxycycline hyclate DR	
Clindagel 75 mL	Coverage requires documentation of serious side effects or drug failure with generic clindamycin AND tretinoin
Clindamycin 1% Gel 75 mL (Oceanside & Solaris)	
Amzeeq	Coverage requires serious side effects or drug failure with TWO topical treatments for acne (erythromycin, clindamycin, tretinoin, adapalene, dapsone, tazarotene)
Zilxi 1.5%	Coverage requires serious side effects or drug failure with topical metronidazole and one additional topical antibiotic (such as clindamycin, erythromycin, azelaic acid).

Pharmacy Management Drug Policy

Step Therapy Policy

ANTICOAGULANTS	
Drug	Requirement
Savaysa	Coverage requires documentation of serious side effects or drug failure with Xarelto (rivaroxaban) or Eliquis
ANTIDEPRESSANTS	
Drug	Requirement
Emsam	Coverage requires documentation of serious side effects or drug failure with at least ONE of the following first line agents: escitalopram, fluoxetine, citalopram, sertraline, paroxetine, mirtazapine, bupropion or venlafaxine immediate-release tablets or venlafaxine extended-release capsules
Forfivo XL 450 mg	
Venlafaxine ER Tablets	Coverage requires documentation of serious side effects or drug failure with venlafaxine ER capsules, however: <ul style="list-style-type: none"> • Equal doses of venlafaxine HCL extended-release tablets are bioequivalent to venlafaxine ER capsules, but are not substitutable at the pharmacy level • A daily dose of 225 mg venlafaxine ER may be obtained by ordering venlafaxine ER 75 mg capsules, taken as 3 capsules once daily • A daily dose of 112.5 mg venlafaxine ER may be obtained by ordering venlafaxine ER 37.5 mg capsules, taken as 3 capsules once daily • The claims processing system will not read history for this edit therefore claims will not automatically pay, therefore a manual step therapy request must be made for coverage determination
Drizalma Sprinkle	Coverage requires serious side effects or drug failure with duloxetine
ANTIEMETICS	
Drug	Requirement
Sancuso	Coverage requires documentation of serious side effects or drug failure with ondansetron AND granisetron
ANTIFUNGAL AGENTS	
Drug	Requirement
Ecoza	Coverage requires documentation of serious side effects or drug failure with TWO of the following generic topical antifungals: ciclopirox, econazole, ketoconazole, nystatin
Econazole nitrate 1% foam	
Ertaczo	
Luzu	
Luliconazole	
Naftin	
Naftifine	
Xolegel	
Oxistat Lotion	
ANTIMIGRAINE AGENTS	
Drug	Requirement
Onzetra Spray	Coverage requires documentation of serious side effects or drug failure with TWO generic triptans:(Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan)
Zomig Nasal Spray/Zolmitriptan Nasal Spray	

Pharmacy Management Drug Policy

Step Therapy Policy

Tosymra	Coverage requires documentation of serious side effects or drug failure with generic sumatriptan nasal spray AND ONE generic oral triptan: (Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan)	
Zembrace	Coverage requires documentation of serious side effects or drug failure with injectable sumatriptan	
ANTIPSYCHOTICS		
Drug	Diagnosis	Requirement
Caplyta	Schizophrenia	Coverage requires documentation of serious side effects or drug failure with TWO generic atypical antipsychotics
	Bipolar Depression	Coverage requires documentation of serious side effects or drug failure with TWO alternative therapies for bipolar depression
	Major Depressive Disorder	Coverage requires documentation of serious side effects or drug failure with TWO different antidepressants (with different mechanisms of action) used in combination OR ONE antidepressant in combination with ONE other augmentation therapy (such as atypical antipsychotic, lithium, buspirone)
Fanapt	Schizophrenia	Coverage requires documentation of serious side effects or drug failure with TWO generic atypical antipsychotics
	Bipolar Disorder	
Rexulti	Schizophrenia	Coverage requires documentation of serious side effects or drug failure with TWO generic atypical antipsychotics
	Major Depressive Disorder	Coverage requires documentation of serious side effects or drug failure with TWO different antidepressants (with different mechanisms of action) used in combination OR ONE antidepressant in combination with ONE other augmentation therapy (such as atypical antipsychotic, lithium, buspirone)
	Agitation associated with Dementia due to Alzheimer disease	Requests for this diagnosis will be approved.
Secuado	Schizophrenia	Coverage requires documentation of serious side effects or drug failure with TWO generic atypical antipsychotics
Vraylar	Schizophrenia	Coverage requires documentation of serious side effects or drug failure with TWO generic atypical antipsychotics
	Bipolar disorder	
	Bipolar Depression	Coverage requires documentation of serious side effects or drug failure with TWO alternative therapies for bipolar depression
	Major Depressive Disorder	Coverage requires documentation of serious side effects or drug failure with TWO different antidepressants (with different mechanisms of action) used in combination OR ONE antidepressant in combination with ONE other augmentation therapy (such as atypical antipsychotic, lithium, buspirone)
ANTIVIRALS		
Drug	Requirement	
Acyclovir 5% cream	Coverage requires documentation of serious side effects or drug failure with acyclovir 5% ointment.	
Penciclovir 1% cream		
Xerese 5%-1% cream		
Zovirax 5% cream	Coverage requires documentation of serious side effects or drug failure with acyclovir 5% ointment AND generic acyclovir 5% cream	

Pharmacy Management Drug Policy

Step Therapy Policy

Denavir 1% cream	Coverage requires documentation of serious side effects or drug failure with acyclovir 5% ointment AND generic penciclovir 1% cream
BLOOD GLUCOSE REGULATORS	
(SELECT BENEFITS ONLY)	
Drug	Requirement
Admelog	Coverage requires documentation of serious side effects or drug failure with Humalog, Humalog Mix 75/25, or Insulin Lispro (Lilly unbranded version)
Apidra	
Fiasp	
Kirsty, Kirsty pen	
Novolog, Novolog Mix 70/30, Insulin Aspart	
Lyumjev	
Novolin 70-30, Novolin N, Novolin R	Coverage requires documentation of serious side effects or drug failure with corresponding Humulin product (N, R, 70-30)
Tresiba, Insulin degludec	Coverage requires documentation of serious side effects or drug failure with ONE of the following: Lantus, insulin glargine, insulin glargine-yfgn, Toujeo
Nesina	Coverage requires documentation of serious side effects or drug failure with Tradjenta or Jentadueto
Alogliptin	
Kazano	
Alogliptin/metformin	
Oseni	
Alogliptin/pioglitazone	
Glumetza	Coverage requires documentation of serious side effects or drug failure with generic immediate-release metformin AND generic extended-release metformin (generic equivalent of Glucophage XR)
Fortamet	
Metformin ER (generics of Fortamet and Glumetza), Metformin HCl 625 mg	
Blood Glucose Meters and Test Strips	<p><u>For patients aligned to 2025 formularies:</u> Coverage of any non-preferred blood glucose meter or test strip requires either: a previous trial and failure OR the inability to use any Abbott (Freestyle or Precision Xtra) or One Touch products</p> <p><u>For patients aligned to 2026 formularies:</u> Coverage of any non-preferred blood glucose meter or test strip requires either: a previous trial and failure OR the inability to use any Abbott (Freestyle or Precision Xtra) or Contour products</p>
Qtern	Coverage requires documentation of serious side effects OR drug failure with Glyxambi
Invokamet, Invokamet XR, Segluromet	<p><u>For patients aligned to 2025 formularies:</u> Coverage requires documentation of serious side effects or drug failure with Xigduo XR AND Synjardy/Synjardy XR</p> <p><u>For patients aligned to 2026 formularies:</u> Coverage requires documentation of serious side effects or drug failure with Xigduo XR</p>

Pharmacy Management Drug Policy

Step Therapy Policy

Synjardy, Syndardy XR	Coverage requires documentation of serious side effects or drug failure with Xigduo XR
Invokana, Steglatro	<u>For patients aligned to 2025 formularies:</u> Coverage requires documentation of serious side effects or drug failure with Farxiga AND Jardiance <u>For patients aligned to 2026 formularies:</u> Coverage requires documentation of serious side effects or drug failure with Farxiga
Jardiance	Coverage requires documentation of serious side effects or drug failure with Farxiga
Januvia (sitagliptin), Janumet and Janumet XR (sitagliptin and metformin)	Coverage requires documentation of serious side effects or drug failure with Tradjenta, Jentadueto, or Jentadueto XR
Steglujan (ertugliflozin/sitagliptin)	Coverage requires documentation of serious side effects or drug failure with Glyxambi

CARDIOVASCULAR AGENTS

Drug	Requirement
Edarbi	Coverage requires documentation of serious side effects or drug failure with TWO of the following: losartan, irbesartan, valsartan
Edarbyclor	Coverage requires documentation of serious side effects or drug failure with TWO of the following: losartan/hctz, irbesartan/hctz, valsartan/hctz
Thalitone	Coverage requires documentation of serious side effects or drug failure with generic chlorthalidone.

CARDIOVASCULAR AGENTS, DYSLIPIDEMICS

Drug	Requirement
Livalo	Documentation of serious side effects or drug failure with TWO of the following generic statins: atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
Pitavastatin	
Calcium Zypitamag	
Praluent	Coverage requires documentation of serious side effects or drug failure Repatha for those aged 10 years and older.
Nexletol, Nexlizet	Coverage requires documentation of serious side effects or drug failure with one generic statin: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin

NEUROLOGICAL AGENTS

Drug	Requirement
Savella	Coverage requires documentation of serious side effects or drug failure with duloxetine
Adlarity	Coverage requires documentation of serious side effects or drug failure of donepezil, donepezil ODT, galantamine, OR rivastigmine

DERMATOLOGICAL AGENTS

Drug	Requirement
Aczone 7.5%, Dapsone 7.5%	Coverage requires documentation of serious side effects or drug failure with a topical retinoid AND Dapsone 5%
Adapalene 0.1% Lotion, Soln, Swab	Coverage requires documentation of serious side effects or drug failure with adapalene cream or gel AND tretinoin cream or gel
Differin 0.1% Lotion	

Pharmacy Management Drug Policy

Step Therapy Policy

Eucrisa Ointment	Coverage requires documentation of serious side effects or drug failure with ONE generic topical steroid (aclometasone, amcinonide, betamethasone, clobetasol, desonide, desoximetasone, diflorasone, fluocinolone, fluocinonide–E, fluticasone, halobetasol, hydrocortisone 2.5%, hydrocortisone valerate, mometasone, prednicarbate, triamcinolone) OR ONE of the following: tacrolimus ointment or pimecrolimus cream.
Noritate	Coverage requires documentation of serious side effects or drug failure with generic metronidazole cream, gel, or lotion
Zyclara 2.5% Cream Pump, Zyclara 3.75% Cream and Zyclara 3.75% Cream Pump	Coverage requires documentation of serious side effects or drug failure with imiquimod 5% cream
Imiquimod 3.75% Cream, and Imiquimod 3.75% Cream Pump	

GASTROINTESTINAL AGENTS

Drug		Requirement
Amitiza	Chronic idiopathic constipation or IBS-C	<p><u>For patients aligned to 2025 formularies:</u> Coverage requires documentation of serious side effects or drug failure with lubiprostone AND either Linzess OR Trulance for a diagnosis of chronic idiopathic constipation or irritable bowel syndrome with constipation.</p> <p><u>For patients aligned to 2026 formularies:</u> Coverage requires documentation of serious side effects or drug failure with lubiprostone AND Trulance for a diagnosis of chronic idiopathic constipation or irritable bowel syndrome with constipation.</p>
	Opioid-induced constipation	Coverage requires documentation of drug failure or serious side effects with lubiprostone AND Movantik for a diagnosis of opioid induced constipation.
Motegrity		<p><u>For patients aligned to 2025 formularies:</u> Coverage requires documentation of serious side effects or drug failure with prucalopride AND Linzess OR Trulance for a diagnosis of chronic idiopathic constipation (CIC)</p> <p><u>For patients aligned to 2026 formularies:</u> Coverage requires documentation of serious side effects or drug failure with prucalopride AND Trulance for a diagnosis of chronic idiopathic constipation (CIC)</p>
Linzess	Chronic idiopathic constipation	Coverage requires documentation of serious side effects or drug failure with TWO of the following: lubiprostone, prucalopride, Trulance
	IBS-C	Coverage requires documentation of serious side effects or drug failure with TWO of the following: lubiprostone, Trulance

Pharmacy Management Drug Policy

Step Therapy Policy

	Functional constipation in pediatric patients 6-17 years of age	Requests for this diagnosis will be approved
Relistor Tablet		Coverage requires documentation of serious side effects or drug failure with lubiprostone AND Movantik for a diagnosis of opioid-induced constipation
Symproic		
Ibsrela		<p><u>For patients aligned to 2025 formularies:</u> Coverage requires documentation of serious side effects or drug failure with TWO of the following: prucalopride, lubiprostone, Linzess, Trulance for a diagnosis of irritable bowel syndrome with constipation</p> <p><u>For patients aligned to 2026 formularies:</u> Coverage requires documentation of serious side effects or drug failure with TWO of the following: lubiprostone, Trulance for a diagnosis of irritable bowel syndrome with constipation</p>
Omeprazole/Sodium Bicarbonate Packets		Coverage requires documentation of serious side effects or drug failure with TWO of the following: omeprazole, pantoprazole, lansoprazole, rabeprazole
Zegerid Packets		
Pheburane		Coverage requires documentation of serious side effects or drug failure with generic sodium phenylbutyrate

GENITOURINARY AGENTS

Drug		Requirement
Oxytrol		Coverage requires documentation of serious side effects or drug failure with TWO of the following: oxybutynin, oxybutynin ER, tolterodine, trospium, trospium XR Exception: Gelnique does not require step therapy for individuals 65 years of age or older
Gelnique		
Myrbetriq	Adult Overactive Bladder (OAB)	Coverage requires documentation of serious side effects or drug failure with mirabegron ER AND Gemtesa
	Pediatric Neurogenic Detrusor Overactivity (NDO)	Patients 5 years of age and older must have had serious side effects or drug failure of oxybutynin tablets or syrup a. Patients with difficulty swallow oxybutynin tablets must try the syrup

HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (ADRENAL)

Drug		Requirement
Bryhali		Coverage requires documentation of a serious side effects or drug failure with TWO of the following generic topical steroids:
Cloderm, Clocortolone Pivalate		
Cordran (Cream, Lotion, Ointment)		
Desonide 0.05% Gel		
Halog, Halcinonide		

Pharmacy Management Drug Policy

Step Therapy Policy

Halobetasol Propionate 0.05% Foam	aclometasone, amcinonide, betamethasone, clobetasol, desonide, desoximetasone, diflorasone, fluocinolone, fluocinonide–E, fluticasone, halobetasol (except foam), hydrocortisone 2.5%, hydrocortisone valerate, hydrocortisone butyrate (except lotion), mometasone, prednicarbate, triamcinolone
Impeklo	
Impoyz Cream (and generic clobetasol 0.025% cream)	
Lexette	
Pandel	
Sernivo Lotion	
Ultravate Lotion	
Verdeso	

IMMUNOLOGICAL AGENTS

Drug	Requirement
Prograf Granules	Must have documentation of serious side effects or drug failure with generic tacrolimus capsules Exception: age less than 9 years old

MULTIPLE SCLEROSIS AGENTS

Drug	Requirement
Ponvory	Coverage requires documentation of serious side effects or drug failure with TWO of the following agents: Avonex, Copaxone 40mg, glatiramer, Glatopa, fingolimod, dimethyl fumarate, Mayzent, Plegridy, Rebif, teriflunomide, Kesimpta, or Zeposia.
Vumerity	Coverage requires documentation of a trial of dimethyl fumarate (generic Tecfidera) that resulted in gastrointestinal (GI) intolerance AND a trial of ONE preferred agent (Avonex, Copaxone 40mg, glatiramer, Glatopa, fingolimod, Mayzent, Plegridy, Rebif, teriflunomide, Kesimpta, or Zeposia)

OPHTHALMIC AGENTS

Drug	Requirement
Zerviate	Coverage requires documentation of serious side effects or drug failure with TWO of the following antihistamine eye drops: azelastine, olopatadine, epinastine
Xelpros	Coverage requires documentation of serious side effects or drug failure with Lumigan AND either latanoprost or travoprost
Vyzulta	
Zioptan	
Iyuzeh	
Tafluprost	
Rhopressa, Rocklatan	Coverage requires documentation of serious side effects or drug failure with any covered prostaglandin analogue (such as bimatoprost, travoprost, latanoprost, Lumigan)
Restasis 0.05%	Coverage requires documentation of serious side effects or drug failure of cyclosporine 0.05% eye emulsion AND Xiidra 5% eye drops
Restasis Multidose 0.05%	
Atropine Sulfate/PF	Coverage requires documentation of serious side effects or drug failure of generic atropine 1% drops

PANCREATIC ENZYMES

Drug	Requirement
Pancreaze	Coverage requires documentation of serious side effects or drug failure with Creon and Zenpep
Pertzye	

RESPIRATORY TRACT/PULMONARY AGENTS

Drug	Requirement
------	-------------

Pharmacy Management Drug Policy

Step Therapy Policy

Tudorza Pressair	Coverage requires documentation of serious side effects or drug failure with ONE of the following: tiotropium bromide or Incruse.
Alvesco	Coverage requires documentation of serious side effects or drug failure with ONE of the following: Arnuity Ellipta, Asmanex, or Qvar Redihaler.
Pulmicort Flexhaler	
Armonair Digihaler	
AirDuo Respiclick	
AirDuo Digihaler	Coverage requires documentation of severe intolerance or therapeutic failure with generic fluticasone/salmeterol inhaler
Lonhala Magnair 25 mcg Starter	Coverage requires documentation of serious side effects or drug failure with any TWO of the following long-acting muscarinic receptor antagonists (LAMA) containing inhalers: Anoro Ellipta, Bevespi Aerosphere, Incruse Ellipta, Neohaler, tiotropium bromide Handihaler, Spiriva Respimat, Stiolto Respimat, or Utibron
Lonhala Magnair 25 mcg Refill	
Yupelri	
Duaklir Pressair	Coverage requires serious side effects or drug failure with at least TWO long-acting muscarinic receptor antagonist/long-acting beta agonist (LAMA/LABA) agents. Agents include: Anoro, Bevespi, Stiolto and Utibron.

SELECTIVE ESTROGEN RECEPTOR MODIFYING AGENTS

Drug	Requirement
Estring	Coverage requires documentation of serious side effects or drug failure with a topical vaginal estrogen product such as Premarin cream or estradiol vaginal cream.
Osphena	

SKELETAL MUSCLE RELAXANTS

Drug	Requirement
Norgesic Forte	Coverage requires documentation of serious side effects or drug failure with TWO of the following (generic) agents: baclofen, carisoprodol, chlorzoxazone, cyclobenzaprine, methocarbamol, metaxalone, orphenadrine, tizanidine
Orphengesic Forte	
Orphenadrine/ Aspirin/Caffeine	

SLEEP DISORDER AGENTS

Drug	Requirement
Edluar	Coverage requires documentation of serious side effects or drug failure with zolpidem
Belsomra, Dayvigo, Quviviq	Coverage requires documentation of serious side effects or drug failure with TWO of the following: zolpidem, eszopiclone, zaleplon

POLICY GUIDELINES:

1. This policy is applicable to drugs that are included on a specific drug formulary. If a drug referenced in this policy is non-formulary, please reference the Coverage Exception Evaluation Policy for All Lines of Business Formularies policy for review guidelines.
2. Supportive documentation of previous drug use must be submitted for any criteria requiring trial of a preferred agent if the preferred drug is not found in claims history.
3. Approval for step therapy requirements may not bypass MAC penalty. Please see MAC penalty policy for detail of this benefit.
4. Utilization Management are contract dependent and coverage criteria may be dependent on the contract renewal date. Additionally, coverage of drugs listed in this policy are contract dependent. Refer to specific contract/benefit language for exclusions.
5. For contracts where Insurance Law § 4903(c-1), and Public Health Law § 4903(3-a) are applicable, if trial of preferred drug(s) is the only criterion that is not met for a given condition, and one of the

Pharmacy Management Drug Policy

Step Therapy Policy

following circumstances can be substantiated by the requesting provider, then trial of the preferred drug(s) will not be required.

- a. The required prescription drug(s) is (are) contraindicated or will likely cause an adverse reaction or physical or mental harm to the member;
 - b. The required prescription drug is expected to be ineffective based on the known clinical history and conditions and concurrent drug regimen;
 - c. The required prescription drug(s) was (were) previously tried while under the current or a previous health plan, or another prescription drug or drugs in the same pharmacologic class or with the same mechanism of action was (were) previously tried and such prescription drug(s) was (were) discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event;
 - d. The required prescription drug(s) is (are) not in the patient's best interest because it will likely cause a significant barrier to adherence to or compliance with the plan of care, will likely worsen a comorbid condition, or will likely decrease the ability to achieve or maintain reasonable functional ability in performing daily activities;
 - e. The individual is stable on the requested prescription drug. The medical profile of the individual (age, disease state, comorbidities), along with the rationale for deeming stability as it relates to standard medical practice and evidence-based practice protocols for the disease state will be taken into consideration.
 - f. The above criteria are not applicable to requests for brand name medications that have an AB rated generic. We can require a trial of an AB-rated generic equivalent prior to providing coverage for the equivalent brand name prescription drug.
6. Initial approval will be granted for a period of 1 year.
 - Continued approval at time of recertification will require documentation that the drug is providing ongoing benefit to the patient in terms of improvement or stability in disease state or condition.
 7. Clinical documentation must be submitted for each request (initial and recertification) unless otherwise specified (e.g., provider attestation required). Supporting documentation includes, but is not limited to, progress notes documenting previous treatments/treatment history, diagnostic testing, laboratory test results, genetic testing/biomarker results, imaging and other objective or subjective measures of benefit which support continued use of the requested product is medically necessary. Also, ongoing use of the requested product must continue to reflect the current policy's preferred formulary. Recertification reviews may result in the requirement to try more cost-effective treatment alternatives as they become available (i.e., generics, biosimilars, or other guideline supported treatment options). Requested dosing must continue to be consistent with FDA-approved or off-label/guideline-supported dosing recommendations.
 8. In addition to the full prescribing information for each individual drug, the corresponding clinical guidelines (i.e., NCCN, DSM, etc.) are reviewed on an annual basis to determine the appropriateness of the medical necessity criteria that is applied.
 9. All requests will be reviewed to ensure they are being used for an appropriate indication and may be subject to an off-label review in accordance with our Off-Label Use of FDA Approved Drugs Policy (Pharmacy-32)
 10. All utilization management requirements outlined in this policy are compliant with applicable New York State insurance laws and regulations. Policies will be reviewed and updated as necessary to ensure ongoing compliance with all state and federally mandated coverage requirements.
 11. For Fully Insured Commercial and Exchange products only: New York State insurance requirements prohibit negative mid-plan-year formulary changes. Therefore, members enrolled in non-calendar-year plans (e.g., July-July renewals) may continue to follow the prior plan year's formulary tier structure and corresponding utilization-management criteria until their group's renewal date.
 - a. Pharmacy Benefit Formulary ID Alignment

Pharmacy Management Drug Policy

Step Therapy Policy

- i. 2025 Commercial/Exchange Formulary IDs: 5181,5899,2981
- ii. 2026 Commercial/Exchange/Essential Plan/Child Health Plus Formulary IDs: 2950,6262,3295,6264,6060,2977,5930

UPDATES:

Date	Revision
02/16/2026	Revised
01/01/2026	Revised
11/20/2025	Revised
11/13/2025	P&T Committee Review / Approval
10/09/2025	Revised
09/08/2025	Revised
09/02/2025	Revised
03/13/2025	Revised
03/06/2025	Revised
01/01/2025	Revised
11/21/2024	P&T Committee Review / Approval
10/21/2024	Revised
09/23/2024	Revised
09/13/2024	Revised
08/13/2024	Revised
05/10/2024	Revised
04/09/2024	Revised
03/14/2024	Revised
02/08/2024	Revised
01/01/2024	Revised
12/06/2023	Revised
11/30/2023	P&T Committee Approval
11/10/2023	Revised
9/7/2023	Revised
8/10/2023	Revised
7/7/2023	Revised
6/8/2023	Revised
4/24/2023	Revised
4/5/2023	Revised
3/31/2023	Revised
3/16/2023	Revised
2/9/2023	Revised
2/3/2023	Revised
12/20/2022	Revised
12/15/2022	Revised
12/2/22	Revised
11/17/2022	P&T Committee Approval
11/3/22	Revised
10/3/22	Revised
8/29/22	Revised
8/25/22	Revised
7/28/22	Revised

Pharmacy Management Drug Policy

Step Therapy Policy

6/30/22	Revised
6/3/22	Revised
5/12/22	Revised
5/9/2022	Revised
05/05/2022	P&T Committee Approval
5/1/2022	Revised
3/29/22	Revised
3/18/22	Revised
2/18/22	Revised
2/8/22	Revised / P&T Committee Approval
1/22	Revised
12/21	Revised
11/21	Revised
10/21	Revised
9/21	Revised
8/21	Revised
5/21	Revised
4/21	Revised
3/21	Revised
2/11/2021	P&T Committee Approval
1/21	Revised
12/20	Revised
10/20	Revised
8/2020	Revised
7/2020	Revised
6/2020	Revised
5/2020	Revised
3/20	Revised
2/20	Revised
1/20	Revised
12/19	Revised
11/19	Revised
10/19	Revised
8/19	Revised
7/19	Revised
5/19	P&T Committee Approval
4/19	Revised
3/19	Revised
2/19	Revised
1/19	Revised
11/18	Revised
10/18	Revised
9/18	Revised
5/18	Revised
4/18	Revised
3/18	Revised
2/18	Revised

Pharmacy Management Drug Policy

Step Therapy Policy

1/18	Revised- Both STEP Policies combined to one policy The Commercial Open step therapy and Exchange Closed/CHP policies have been merged. The policy has also been changed into a table format with headers that match the web formularies (derived from RxFlex).
12/17	Revised
11/2017	P&T Committee Approval
9/17	Revised
7/17	Revised
5/17	Revised
4/17	Revised
1/17	Revised
10/16	Revised
9/16	Revised
8/16	Revised
7/16	Revised
6/16	Revised
5/16	Revised
4/16	Revised
3/16	Revised
1/16	Revised
12/15	Revised
11/15	Revised
8/15	Revised
7/15	Revised
6/15	Revised
5/15	Revised
4/15	Revised
3/15	Revised
1/15	Revised
11/14	Revised
10/14	Revised
8/14	Revised
7/14	Revised
5/14	Revised
3/14	Revised
1/14	Created